Opus Genetics, Inc. (FRA:R3X1)
Germany · Delayed Price · Currency is EUR | Market Cap | 257.80M +143.5% |
| Revenue (ttm) | 8.63M -36.1% |
| Net Income | -94.19M |
| EPS | -1.15 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 950 |
| Open | 3.340 |
| Previous Close | 3.340 |
| Day's Range | 3.040 - 3.340 |
| 52-Week Range | 1.464 - 5.400 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About Opus Genetics
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets ... [Read more]
Financial Performance
In 2025, Opus Genetics's revenue was $14.20 million, an increase of 29.15% compared to the previous year's $10.99 million. Losses were -$49.59 million, -13.80% less than in 2024.
Financial numbers in USD Financial StatementsNews
Opus Genetics announces FDA clearance of OPGx-RDH12 IND application
Opus Genetics (IRD) announced that the FDA has cleared its investigational new drug, or IND, application for OPGx-RDH12, an investigational gene therapy for the treatment of RDH12-associated Leber con...
Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness
FDA clearance enables clinical development of OPGx-RDH12 for RDH12-associated Leber congenital amaurosis, a rare inherited retinal disease that causes progressive vision loss beginning in early childh...
Opus Genetics Transcript: Chardan's 10th Annual Healthcare Conference
FDA approval of phentolamine brings a $10M milestone, while LCA5 dosing is underway and BEST1 Cohort 2 data are expected in Q2 2027. Current funding plans support five programs and runway into 2029, excluding voucher proceeds.
Opus Genetics Slides: Chardan's 10th Annual Healthcare Conference
Opus Genetics has posted slides in relation to its latest quarterly earnings report, which was published on October 20, 2026.
Opus Genetics reports FDA approval of phentolamine ophthalmic solution 0.75%
Opus Genetics (IRD) announced that the U.S. Food and Drug Administration has approved the company’s supplemental New Drug Application for phentolamine ophthalmic solution 0.75% for the treatment of pr...
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
FDA expands the approved use of phentolamine ophthalmic solution 0.75% to include age-related near vision impairment, which affects millions of adults in the United States Approval supported by positi...
Opus Genetics presents clinical findings from its OPGx-BEST1, OPGx-LCA5 programs
Opus Genetics (IRD) presented clinical findings from its OPGx-BEST1 and OPGx-LCA5 gene therapy programs at Retina in Rio 2026 in Rio de Janeiro, Brazil. The company presented findings from the…
Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
OPGx-BEST1 showed improved retinal sensitivity in 75% of evaluable participants in the initial low-dose Cohort 1 of the Company's Phase 1/2 clinical trial, supporting further clinical development New ...
Opus Genetics to Present at the Chardan Annual Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapi...
Opus Genetics management to meet with Oppenheimer
Meeting to be held in New York on October 19 hosted by Oppenheimer.
Opus Genetics price target raised to $17 from $10 at Jones
Jones raised the firm’s price target on Opus Genetics (IRD) to $17 from $10 and keeps a Buy rating on the shares following the OPGx-BEST1 data presentation. Microperimetry was the…
Opus Genetics Slides: Investor presentation
Opus Genetics has posted slides in relation to its latest quarterly earnings report, which was published on September 29, 2026.
Opus Genetics price target raised to $14 from $11 at Leerink
Leerink raised the firm’s price target on Opus Genetics (IRD) to $14 from $11 and keeps an Outperform rating on the shares. The company’s low-dose Cohort 1 of BIRD-1, its…
Opus Genetics price target raised to $20 from $10 at Oppenheimer
Oppenheimer raised the firm’s price target on Opus Genetics (IRD) to $20 from $10 and keeps an Outperform rating on the shares after the company reported results from the low-dose…
Opus Genetics price target raised to $16 from $13 at Chardan
Chardan analyst Andreas Argyrides raised the firm’s price target on Opus Genetics (IRD) to $16 from $13 and keeps a Buy rating on the shares following positive low-dose proof-of-concept data…
Opus Genetics Transcript: Study result
The phase I/II trial of OPGX-BEST1 in BVMD and ARB showed strong safety and promising efficacy, with all participants experiencing functional gains and most showing structural improvements. FDA alignment on a three-decibel microperimetry endpoint and patient-reported outcomes supports pivotal trial planning.
Opus Genetics Slides: Study result
Opus Genetics has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Opus Genetics Press release: Study result
Opus Genetics issued a press release on September 9, 2026, disclosing material business information to investors.
Opus Genetics Slides: Corporate presentation
Opus Genetics has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Opus Genetics announces results from low-dose Cohort 1 of BIRD-1 trial
Opus Genetics (IRD) announced 3- and 6-month results from the low-dose Cohort 1 of BIRD-1, its ongoing Phase 1/2 clinical trial evaluating OPGx-BEST1 in patients with BEST1-related retinal diseases, i...
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027
OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improv...
Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences
Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during investor conference call and webcast on September 9 at 8:00 a.m. ET Full clinical dataset and additional ...
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent bl...
Opus Genetics price target lowered to $9 from $10 at RBC Capital
RBC Capital lowered the firm’s price target on Opus Genetics (IRD) to $9 from $10 and keeps an Outperform rating on the shares.
Opus Genetics Registration statement: Registration filing
Opus Genetics filed a registration statement on August 7, 2026, providing details about a securities offering with the SEC.